SCHEMBL31358769

SCHEMBL31358769

COC(=O)c1ccc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.66
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
MAPT P10636 6/20 0.57
POLB P06746 5/20 0.57
KDM4E B2RXH2 5/20 0.57
L3MBTL1 Q9Y468 4/20 0.57
ALDH1A1 P00352 4/20 0.57
CTDSP1 Q9GZU7 3/20 0.57
PTPN1 P18031 2/20 0.57
AKT1 P31749 1/20 0.57
PPM1G O15355 1/20 0.57
PTPN7 P35236 1/20 0.57
PTPN5 P54829 1/20 0.57
PTPRO Q16827 1/20 0.57
PTPN22 Q9Y2R2 1/20 0.57
HSPD1 P10809 1/20 0.56
HSPE1 P61604 1/20 0.56
PTPRC P08575 1/20 0.53
PTPRF P10586 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358657 0.87 MAPT (0.65) SIRT2MEN1KMT2AMAPTPOLB
SCHEMBL31358833 0.87 PIK3CG (0.61) SIRT2MEN1KMT2AMAPTPOLB
SCHEMBL31358710 0.85 MEN1 (0.68) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL31358678 0.82 KDM4E (0.70) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL31358826 0.82 KMT2A (0.64) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL31358740 0.82 SIRT2 (0.53) SIRT2MEN1KMT2AMAPTPOLB
SCHEMBL31358764 0.82 AKT1 (0.62) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL31358773 0.80 MEN1 (0.69) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL31358723 0.80 MEN1 (0.72) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL5163809 0.80 SIRT2 (1.00) SIRT2MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 SIRT2 4314/4885MEN1 2467/4885KMT2A 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.